AT&T Inc. (T)

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 21 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $29.6, which forecasts a 6.67% increase in the stock price over the next year. The lowest target is $18 and the highest is $34.

Price Target: $29.60 (+6.67%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$18	$29.6	$30	$34
Change	-35.14%	+6.67%	+8.11%	+22.52%

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	6	6	6	6	6	7
Buy	9	8	9	9	9	11
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	18	17	18	18	18	21

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Frank Louthan Raymond James	Raymond James	Strong Buy Reiterates $30 → $31	Strong Buy	Reiterates	$30 → $31	+11.71%	Jul 24, 2025
Sebastiano Petti JP Morgan	JP Morgan	Buy Maintains $31 → $33	Buy	Maintains	$31 → $33	+18.92%	Jul 24, 2025
Simon Flannery Morgan Stanley	Morgan Stanley	Buy Maintains $31 → $32	Buy	Maintains	$31 → $32	+15.32%	Jul 16, 2025
Kevin Fisk Scotiabank	Scotiabank	Buy Maintains $30 → $30	Buy	Maintains	$30 → $30	+8.11%	Jul 11, 2025
Eric Luebchow Wells Fargo	Wells Fargo	Buy Maintains $30 → $31	Buy	Maintains	$30 → $31	+11.71%	Jul 10, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

127.45B

Increased by 4.18%

from 122.34B

Revenue Next Year

129.20B

Increased by 1.37%

from 127.45B

EPS This Year

2.09

Increased by 40.53%

from 1.49

EPS Next Year

2.28

Increased by 8.89%

from 2.09

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	143.05B	134.04B	120.74B	122.43B	122.34B	127.45B	129.20B	131.28B
Revenue Growth	-21.05%	-6.30%	-9.92%	1.40%	-0.08%	4.18%	1.37%	1.61%
EPS	-0.75	2.73	-1.13	1.97	1.49	2.09	2.28	2.55
EPS Growth	-	-	-	-	-24.25%	40.53%	8.89%	11.73%
Forward PE	-	-	-	-	-	13.25	12.17	10.89
No. Analysts	-	-	-	-	-	29	28	23

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	132.3B	134.8B	137.1B
Avg	127.5B	129.2B	131.3B
Low	121.4B	122.8B	123.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	8.2%	5.7%	6.2%
Avg	4.2%	1.4%	1.6%
Low	-0.8%	-3.6%	-4.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	2.37	2.52	2.90
Avg	2.09	2.28	2.55
Low	1.94	1.90	2.06

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	59.3%	20.5%	27.2%
Avg	40.5%	8.9%	11.7%
Low	30.2%	-9.2%	-9.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.